NCT04917133: HUNT'ACTIV

Adapted Physical Activity Effect on Abilities and Quality of Life of Huntington Patients and Relatives During Rehab Stay

Completed NA Last updated 16 September 2022

What this trial tests

NA trial testing Adapted Physical Activity program in Huntington Disease in 32 participants. Completed in 7 December 2021.

Timeline

7 June 2021

Primary endpoint
7 December 2021

7 December 2021

Quick facts

Lead sponsor	Assistance Publique - Hôpitaux de Paris
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	supportive care
Enrollment	32
Start date	7 June 2021
Primary completion	7 December 2021
Estimated completion	7 December 2021
Sites	1 location across France

Drugs / interventions tested

• Adapted Physical Activity program
• Control

Conditions studied

• Huntington Disease — all drugs for Huntington Disease →

Sponsor

Assistance Publique - Hôpitaux de Paris — full company profile →

Who can join

18 and older, any sex, with Huntington Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Intro:

Huntington's disease is a neurodegenerative disease that affects the brain, inducing a dysfunction and death of the middle spiny striatal projection neurons and a progressive alteration of cognitive and motor functions, and psycho-behavioral problems. There is currently no curative treatment but we know hat a multidisciplinary care can optimize the functioning and the quality of life of the patients with Huntington's disease.

A meta-analysis of 18studies indicates that exercise and physical activity can improve motor function, gait speed and balance, and would also improve self-confidence, independence, well-being, reduced apathy and better socialization with family and friends.

Hypothesis/Objective The hypothesis is that the inclusion of a 4 week-program with Adapted Physical Activity (APA) during a rehabilitation stay will improve some motor, cognitive and psycho-behavioral abilities, compared to the control group.

Method

The patients will be randomized into two groups :

The control group will have the "classic" program performed in the standard of care with: kinesitherapy, soft gym, medico-social workshop, cognitive workshop, creative workshop, individual care (rehabilitation, rest, and creation).

The experimental APA group will have in addition of the classic program, 6 APA workshops per week with collective support : Adapted Physical workshops, adapted cycling, therapeutic (horseback/equestrian) riding, cultural or leisure outings, situation tests

For the two groups, at the start of the 4 weeks of rehabilitation program an initial visit will be performed with, as part of this research, a clinical examination, a neurological examination, a dietary consultation, as well as a biological assessment as part of habitual care.

The clinical examination, the neurological examination and the dietary consultation will be performed each week, during the 4 weeks of the program,

At the end of the study, one month after the rehabilitation of the patient, a visit by phone-call will be performed for the patient and his caregiver.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

1. New Avenues for the Treatment of Huntington's Disease.
   Kim A, Lalonde K, Truesdell A, Gomes Welter P, et al · · 2021 · cited 130× · PMID 34445070 · DOI 10.3390/ijms22168363
2. Huntington's Disease Clinical Trials Corner: March 2024.
   Estevez-Fraga C, Tabrizi SJ, Wild EJ. · · 2024 · cited 31× · PMID 38489195 · DOI 10.3233/jhd-240017
3. Huntington's Disease Clinical Trials Corner: August 2023.
   Estevez-Fraga C, Tabrizi SJ, Wild EJ. · · 2023 · cited 22× · PMID 37483021 · DOI 10.3233/jhd-239001
4. Huntington's disease clinical trials update: March 2025.
   Farag M, Tabrizi SJ, Wild EJ. · · 2025 · cited 7× · PMID 40302443 · DOI 10.1177/18796397251337000
5. Huntington's disease clinical trials update: October 2025.
   Farag M, Tabrizi SJ, Wild EJ. · · 2026 · PMID 41295902 · DOI 10.1177/18796397251399751